Short Interest in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Expands By 8.0%

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) was the recipient of a significant increase in short interest in the month of January. As of January 15th, there was short interest totalling 5,530,000 shares, an increase of 8.0% from the December 31st total of 5,120,000 shares. Currently, 10.0% of the company's stock are short sold. Based on an average daily trading volume, of 831,700 shares, the short-interest ratio is currently 6.6 days.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on AGIO shares. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Agios Pharmaceuticals in a report on Wednesday, December 18th. StockNews.com upgraded shares of Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday, November 9th. Raymond James reiterated an "outperform" rating and set a $51.00 price target on shares of Agios Pharmaceuticals in a research note on Thursday, October 10th. Scotiabank upped their target price on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a "sector outperform" rating in a research report on Monday, December 9th. Finally, Royal Bank of Canada raised their price target on Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an "outperform" rating in a research report on Tuesday, December 10th. Five equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat, Agios Pharmaceuticals currently has an average rating of "Hold" and an average price target of $56.33.

Insider Activity

In other Agios Pharmaceuticals news, insider Tsveta Milanova sold 2,804 shares of the stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $32.18, for a total transaction of $90,232.72. Following the transaction, the insider now owns 18,906 shares in the company, valued at approximately $608,395.08. This represents a 12.92 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 4.93% of the company's stock.

Hedge Funds Weigh In On Agios Pharmaceuticals

Large investors have recently bought and sold shares of the company. State Street Corp raised its holdings in shares of Agios Pharmaceuticals by 10.2% in the 3rd quarter. State Street Corp now owns 2,331,433 shares of the biopharmaceutical company's stock worth $103,586,000 after purchasing an additional 216,484 shares during the period. Vestal Point Capital LP purchased a new position in Agios Pharmaceuticals in the third quarter worth $33,767,000. BNP Paribas Financial Markets grew its holdings in shares of Agios Pharmaceuticals by 15.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 11,946 shares of the biopharmaceutical company's stock valued at $531,000 after purchasing an additional 1,570 shares during the last quarter. SG Americas Securities LLC bought a new stake in Agios Pharmaceuticals in the 3rd quarter worth $705,000. Finally, FMR LLC lifted its stake in Agios Pharmaceuticals by 283.2% in the third quarter. FMR LLC now owns 45,393 shares of the biopharmaceutical company's stock worth $2,017,000 after acquiring an additional 33,546 shares during the period.

Agios Pharmaceuticals Stock Performance

Agios Pharmaceuticals stock traded up $0.37 during trading hours on Wednesday, reaching $34.38. 503,295 shares of the company's stock traded hands, compared to its average volume of 768,874. The firm has a market capitalization of $1.96 billion, a price-to-earnings ratio of 3.03 and a beta of 0.88. Agios Pharmaceuticals has a fifty-two week low of $23.41 and a fifty-two week high of $62.58. The firm's 50 day moving average is $39.32 and its 200-day moving average is $44.17.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.